(Q57636872)
Statements
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group (English)
J Thaler
G Gastl
T Fluckinger
D Niederwieser
H Huber
H Seewann
A Lang
M Falk
C Duba
G Utermann
T Kühr
W Aulitzky